Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients | Zendy

Christian Herzmann | Zendy; Zoe Cuthbertson | Zendy; Lisa Fosdick | Zendy; Martin Fisher | Zendy; Mark Nelson | Zendy; Nicky Perry | Zendy; Matthew Law | Zendy; Handan Wand | Zendy; George Janossy | Zendy; Margaret Johnson | Zendy; M Youle | Zendy

Open Access

Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients

Author(s) -

Christian Herzmann,

Zoe Cuthbertson,

Lisa Fosdick,

Martin Fisher,

Mark Nelson,

Nicky Perry,

Matthew Law,

Handan Wand,

George Janossy,

Margaret Johnson,

M Youle

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn238

Subject(s) - medicine , discontinuation , adverse effect , gastroenterology , antiretroviral therapy , cohort , immunology , surgery , human immunodeficiency virus (hiv) , viral load

Subcutaneous administration of interleukin-2 (IL-2) has been shown to increase CD4 counts in HIV-infected patients. It remains unclear whether this effect is associated with a clinical benefit.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research